Atwood & Palmer Inc. Increases Stake in Amgen Inc. $AMGN

Atwood & Palmer Inc. boosted its holdings in Amgen Inc. (NASDAQ:AMGN) by 23.5% in the third quarter, HoldingsChannel.com reports. The firm owned 6,840 shares of the medical research company’s stock after acquiring an additional 1,300 shares during the period. Atwood & Palmer Inc.’s holdings in Amgen were worth $2,883,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently added to or reduced their stakes in AMGN. Rational Advisors Inc. lifted its position in shares of Amgen by 13.7% in the 2nd quarter. Rational Advisors Inc. now owns 199 shares of the medical research company’s stock worth $72,000 after buying an additional 24 shares during the last quarter. Beacon Financial Advisory LLC grew its position in Amgen by 2.0% in the 2nd quarter. Beacon Financial Advisory LLC now owns 1,274 shares of the medical research company’s stock worth $461,000 after purchasing an additional 25 shares during the last quarter. Legacy Financial Advisors Inc. increased its holdings in shares of Amgen by 0.8% during the second quarter. Legacy Financial Advisors Inc. now owns 3,407 shares of the medical research company’s stock valued at $1,234,000 after purchasing an additional 26 shares during the period. Roman Butler Fullerton & Co. raised its position in shares of Amgen by 1.4% during the 2nd quarter. Roman Butler Fullerton & Co. now owns 1,956 shares of the medical research company’s stock worth $705,000 after buying an additional 27 shares in the last quarter. Finally, Round Rock Advisors LLC raised its holdings in Amgen by 2.9% during the second quarter. Round Rock Advisors LLC now owns 1,003 shares of the medical research company’s stock worth $363,000 after purchasing an additional 28 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on AMGN. Wall Street Zen upgraded shares of Amgen from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. HSBC lowered Amgen from a “buy” rating to a “hold” rating and reduced their target price for the company from $445.00 to $425.00 in a report on Thursday, September 10th. Barclays lifted their price target on Amgen from $360.00 to $380.00 and gave the company an “equal weight” rating in a report on Friday, August 14th. Canaccord Genuity Group increased their price objective on Amgen from $366.00 to $384.00 and gave the stock a “hold” rating in a research note on Wednesday, August 5th. Finally, Argus raised their price objective on Amgen from $375.00 to $460.00 and gave the stock a “buy” rating in a research report on Wednesday, August 19th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, sixteen have issued a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, Amgen currently has a consensus rating of “Hold” and a consensus target price of $388.29.

Insider Activity

In related news, SVP Rachna Khosla sold 1,252 shares of the stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $416.43, for a total value of $521,370.36. Following the transaction, the senior vice president owned 6,404 shares in the company, valued at approximately $2,666,817.72. This represents a 16.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Nancy A. Grygiel sold 2,970 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the transaction, the senior vice president directly owned 7,340 shares in the company, valued at approximately $2,951,854.40. The trade was a 28.81% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 6,222 shares of company stock valued at $2,540,926. 0.85% of the stock is owned by corporate insiders.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen announced a new Phase 3 head-to-head trial for its monthly diabetes injection against semaglutide. Success could strengthen Amgen’s position in the growing GLP-1 market and create a significant future revenue opportunity. Amgen’s Monthly Diabetes Shot Takes Aim at Semaglutide in New Phase 3 Trial
• Positive Sentiment: Amgen participated in Arboretum LifeSciences’ $30 million Series A financing for AI-based genetic testing. The investment could give Amgen access to molecular data that supports more targeted clinical-trial design, though the financial impact is likely limited in the near term. Amgen Backs $30 Million Series A Round
• Positive Sentiment: Recent coverage cited positive investor attention following Amgen’s Sjögren’s syndrome trial update, adding another potential development catalyst to the company’s pipeline. Amgen Announces Sjögren’s Trial Results
• Neutral Sentiment: Amgen’s stock had recently advanced and has substantially outperformed the broader market over the past year. Pre-market indications were broadly stable, suggesting investors are weighing pipeline prospects against valuation and analyst caution. What Would It Take For Amgen Stock to Move Higher?
• Negative Sentiment: Morgan Stanley lowered its price target to $359 from $362 and retained an Equal Weight rating. Truist raised its target to $380 but kept a Hold rating; both targets remain below Amgen’s recent trading level, reinforcing concerns that the stock’s rally may have outpaced near-term fundamentals. Morgan Stanley Adjusts Price Target on Amgen

Amgen Stock Down 1.4%

Shares of NASDAQ AMGN traded down $5.64 during mid-day trading on Thursday, reaching $407.44. The company had a trading volume of 2,365,351 shares, compared to its average volume of 2,756,801. Amgen Inc. has a twelve month low of $288.00 and a twelve month high of $447.03. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.13 and a current ratio of 1.37. The stock has a market capitalization of $220.27 billion, a PE ratio of 25.32, a price-to-earnings-growth ratio of 2.90 and a beta of 0.41. The stock’s 50 day moving average is $411.95 and its 200-day moving average is $371.46.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.62 by $0.67. The business had revenue of $10.05 billion during the quarter, compared to analyst estimates of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%.Amgen’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same period last year, the company earned $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, equities analysts anticipate that Amgen Inc. will post 22.94 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, September 11th. Stockholders of record on Friday, August 21st were paid a dividend of $2.52 per share. The ex-dividend date of this dividend was Friday, August 21st. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.5%. Amgen’s dividend payout ratio (DPR) is 62.65%.

Amgen Company Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research and commercial activities focus on areas including oncology, cardiovascular disease, inflammation, bone health, neuroscience and rare diseases. The company uses biologic research, human genetics and other advanced technologies to develop targeted therapies and supports patients through treatment and disease-management services.

Amgen’s portfolio includes medicines such as Enbrel for inflammatory diseases; Prolia and Evenity for osteoporosis; Xgeva for cancer-related bone complications; Repatha for certain cardiovascular conditions; Otezla for inflammatory diseases; Aimovig for migraine prevention; Tezspire for severe asthma; and Lumakras for certain cancers.